NeuroPace, Inc.

NASDAQ:NPCE

Medical - Devices

Healthcare
$8.22 +0.30%

+$0.05 today

Market cap
$283.19M
Beta
1.88
P/E (TTM)
-23.8
EPS (TTM)
-$0.64
52W Low $7.56High $19.60

Volume 0.31M

Average 0.18M

NPCE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

NeuroPace, Inc.NASDAQ: NPCE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $2.28M fell 13.3% year over year, behind the +3.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 12.6% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Stock-based compensation amounted to 11.1% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -13.3% toward the trailing-twelve-month pace of +3.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.28M-12.6% QoQ
Last fiscal yearDec 2025
$11.09M+7.8% YoY
LTMMar 2026
$10.74M+3.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.3%——
1 year+7.8%——
3-year CAGR+9.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.09M USD
Year-over-year change
+7.8%
4-year CAGR
+26.8%

Stock-Based Compensation vs competitors

How NPCE compares with its peers on the latest reported figures

  • NPCE's LTM Mar 2026 stock-based compensation of $10.74M is the smallest of the 2 companies compared; the peer median is $11.51M.
  • Its year-over-year change of +3.6% is the lowest of 2, against a peer median of +11.1%.
  • Stock-based compensation amounts to 10.8% of revenue for NPCE, versus a peer median of 19.5%.
NPCE Competitors Peer median
Stock-Based Compensation for NPCE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CVRXCVRx, Inc.LTM Mar 2026$11.51M +11.1%+41.7%19.5%
NPCENeuroPace, Inc.LTM Mar 2026$10.74M +3.6%+9.9%10.8%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding NPCE) $11.51M+11.1%+41.7%19.5%

Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Depreciation & Amortization296K2.99M1.61M1.77M1.95M
Deferred Income Tax5.48M0000
Stock-Based Compensation4.29M8.35M9.56M10.28M11.09M
Change in Working Capital368K(4.79M)(2.48M)(5.45M)(4.01M)
Accounts Receivables1.3M(391K)(4.85M)(537K)(1.83M)
Inventory(1.16M)(2.13M)(1.7M)251K(3.67M)
Accounts Payables479K647K240K671K(730K)
Other Working Capital(259K)(2.91M)3.82M(5.84M)2.22M
Other Non-Cash Items1.07M3.67M4.58M2.59M1.43M
Operating Cash Flow(24.58M)(36.87M)(19.7M)(17.95M)(11.01M)
Capital Expenditures(384K)(603K)(173K)(306K)(332K)
Acquisitions (Net)00000
Purchases of Investments(85.01M)0000
Sales of Investments024.4M23.2M9.3M0
Other Investing Activities00000
Investing Cash Flow(85.4M)23.8M23.03M8.99M(332K)
Debt Repayment(4.09M)000(2.07M)
Common Stock Issued109.09M07.89M3.28M71.76M
Common Stock Repurchased0000(49.55M)
Dividends Paid00000
Other Financing Activities(2.47M)490K239K1.05M(543K)
Financing Cash Flow102.53M490K8.13M4.33M19.6M
Effect of Forex Changes00000
Net Change in Cash(7.45M)(12.58M)11.45M(4.63M)8.26M
Free Cash Flow(24.96M)(37.47M)(19.87M)(18.26M)(11.34M)

NeuroPace, Inc.

NASDAQ:NPCE

Intrinsic Alpha fair value

Locked

Current Price

$8.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.